Westside Investment Management Inc. Has $717,000 Stake in SPDR S&P Biotech ETF (XBI)

Share on StockTwits

Westside Investment Management Inc. lifted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 30.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 9,990 shares of the exchange traded fund’s stock after purchasing an additional 2,320 shares during the period. Westside Investment Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $717,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of SPDR S&P Biotech ETF by 98.7% during the third quarter. JPMorgan Chase & Co. now owns 3,265,715 shares of the exchange traded fund’s stock worth $313,084,000 after purchasing an additional 1,622,372 shares during the period. Wells Fargo & Company MN lifted its holdings in SPDR S&P Biotech ETF by 10.0% in the third quarter. Wells Fargo & Company MN now owns 1,716,647 shares of the exchange traded fund’s stock worth $164,576,000 after buying an additional 156,483 shares during the period. Rafferty Asset Management LLC lifted its holdings in SPDR S&P Biotech ETF by 114.1% in the third quarter. Rafferty Asset Management LLC now owns 941,464 shares of the exchange traded fund’s stock worth $90,258,000 after buying an additional 501,695 shares during the period. First Republic Investment Management Inc. lifted its holdings in SPDR S&P Biotech ETF by 1.6% in the third quarter. First Republic Investment Management Inc. now owns 523,329 shares of the exchange traded fund’s stock worth $50,171,000 after buying an additional 8,257 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in SPDR S&P Biotech ETF by 306.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 357,610 shares of the exchange traded fund’s stock worth $34,281,000 after buying an additional 269,595 shares during the period.

XBI traded up $0.41 on Monday, hitting $83.09. The company had a trading volume of 164,407 shares, compared to its average volume of 4,916,432. SPDR S&P Biotech ETF has a 52-week low of $64.38 and a 52-week high of $101.55.

TRADEMARK VIOLATION NOTICE: “Westside Investment Management Inc. Has $717,000 Stake in SPDR S&P Biotech ETF (XBI)” was published by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2019/02/11/westside-investment-management-inc-has-717000-stake-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: What are convertible shares? 

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply